BLACKROCK GREATER EUROPE INVESTMENT TRUST plc
All information is at 31 January 2013 and unaudited.
Performance at month end with net income reinvested
One Three One Three Since launch
Month Months Year Years (20 Sep 04)
Net asset value (Undiluted) 10.5% 17.4% 29.2% 38.9% 158.9%
Net asset value (Diluted) 10.5% 18.1% 29.2% 38.9% 159.0%
Share price 10.7% 16.9% 26.7% 41.7% 150.9%
FTSE World Europe ex UK 9.4% 15.7% 23.6% 23.3% 102.8%
Sources: BlackRock and Datastream
At month end
Net asset value (capital only): 221.87p
Net asset value (including income): 222.45p
Net asset value (capital only)**: 221.87p
Net asset value (including income)**: 222.45p
Share price: 214.50p
Discount to NAV (including income): 3.6%
Discount to NAV (including income)**: 3.6%
Gearing: 0.57%
Net yield: 2.0%
Total assets (including income): £260.1m
Ordinary shares in issue: 116,285,355
** Diluted for treasury shares.
*** Excluding 6,052,299 shares held in treasury.
Benchmark
Sector Analysis Total Assets (%) Index (%) Country Analysis Total Assets (%)
Consumer Goods 21.3 19.1 Switzerland 26.5
Industrials 15.1 15.0 Germany 21.1
Financials 13.9 21.5 France 17.4
Health Care 12.6 12.6 Denmark 6.2
Basic Materials 12.6 8.4 Russia 5.7
Oil & Gas 8.9 6.4 Netherlands 4.8
Consumer Services 6.6 5.2 Belgium 4.5
Technology 4.5 3.6 Finland 3.7
Utilities 2.4 4.1 Portugal 2.4
Telecommunications 1.5 4.1 Ireland 2.3
Net current assets 0.6 - Hungary 1.7
----- ----- Sweden 1.4
100.0 100.0 Norway 1.2
===== ===== Other 0.5
Net current assets 0.6
-----
100.0
=====
Ten Largest Equity Investments (in alphabetical order)
Company
BASF Germany
Cie Financière Richemont Switzerland
Continental Germany
Novo Nordisk Denmark
Roche Switzerland
Sanofi France
Schneider Electric France
Swiss Re Switzerland
Volkswagen Germany
Zurich Insurance Switzerland
Commenting on the markets, Vincent Devlin, representing the Investment Manager
noted:
During the month the Company's NAV rose by 10.5% and the share price rose by
10.7%. For reference, the FTSE World Europe ex UK index rose 9.4% during the
same period.
January saw a bullish start to the year in European equity markets, helped by a
combination of decreased tail risk, relative valuation support and flows back
into equities from fixed income. Selected corporate earnings also helped
support the buoyant mood in markets, with aggregate earnings announcements
beating expectations on average following a period of downgrades.
Successful stock selection drove performance in January. Positions in consumer
services and health care proved especially profitable, somewhat offset by
relatively unsuccessful positions within the oil & gas sector.
One of the top-performing stocks in the portfolio during January was Ryanair,
which benefited from continued yield improvement and news of stronger than
expected booking patterns in the second half of 2012. Within industrials, a
position in EADS benefited performance as the stock experienced a very strong
rally in the first few weeks of the year, and a position in Finnish industrial
Kone gained as the company reported positive momentum in its Chinese new
equipment business.
Within health care, a position in Novo Nordisk also performed strongly as the
company reported strong results and as the management team affirmed a very
positive outlook for the business. Semiconductor company ASML also aided
performance. It appears that the semiconductor equipment order cycle is
bottoming and ASML could report better numbers as the year progresses. In
addition, the company gave more clarity on its next generation 2016/7 EUV tool
which is the foundation for ASML next significant up cycle. Other strong
performers included Russian name Sberbank and Belgian retail franchise KBC.
Stock selection in oil & gas was less successful, as holdings in Technip and
CGG Veritas suffered from concerns surrounding the pricing cycle for
exploration projects.
At the end of the month, the Company was positioned overweight basic materials,
consumer services, health care, technology and consumer goods and underweight
telecoms, oil & gas, industrials, financials and utilities. The Company had a
cash position of 0.9% of NAV at the end of the month.
Outlook
After a trough in activity in the summer of 2012, global leading economic
indicators have been improving across the US, Europe and China and the outlook
for 2013 looks brighter than for 2012. This background is supportive for
equities.
Macro momentum remains supportive, with leading indicators continuing to
improve. Earnings growth profile for European companies remains supportive,
although the recent FX moves could put pressure on our 9% earnings growth
prediction. Investor positioning remains low versus history, even if flows
have been coming into the asset class. Valuations of European equities remain
undemanding and the market should remain supported in the mid-term. Given the
rapid rise in the market, we might see some market consolidation in the near
term, but overall we remain positive on the upside potential for Europe.
13 February 2013
ENDS
Latest information is available by typing www.brgeplc.co.uk on the internet,
"BLRKINDEX" on Reuters, "BLRK" on Bloomberg or "8800" on Topic 3 (ICV
terminal). Neither the contents of the Manager's website nor the contents of
any website accessible from hyperlinks on the Manager's website (or any other
website) is incorporated into, or forms part of, this announcement.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.